synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Blood-thinning agents are divided into two groups, antiplatelet drugs and anticoagulants. They are indicated to facilitate smooth blood flow within blood vessels by preventing the formation of blood clots and retarding their growth. Blood clots are formed to prevent an injured blood vessel from excessive bleeding by a mechanism called hemostasis. The body has intrinsic mechanisms to dissolve the blood clot as the injury heals. However, it can be dangerous when clots do not dissolve naturally and develop within vessels, also known as thrombosis. Hence, blood-thinning medications can be prescribed to reduce the risk of cardiovascular diseases led by blood clots, such as myocardial infarction (heart attack), ischemic stroke, and venous thromboembolism. Haemorrhage (internal bleeding) is the most prominent side effect of blood-thinning therapy. Concomitant use of drugs that increase the risk of bleeding is not recommended. Meanwhile, patients should receive education about proper management of cuts, bruises and nosebleeds. The agents can be classified according to different mechanisms of action.
The first group of Directives create a range of individual rights in EU employment relationships. The Employment Information Directive 1991 requires that every employee (however defined by member state law) has the right to a written statement of their employment contract. While there is no wage regulation, the Institutions for Occupational Retirement Provision Directive 2003 requires that pension benefits are protected through a national insurance fund, that information is provided to beneficiaries, and minimum standards of governance are observed. Most member states go far beyond these requirements, particularly by requiring a vote for employees in who manages their money. Reflecting basic standards in the Universal Declaration of Human Rights and ILO Conventions, the Working Time Directive 2003 requires a minimum of 4 weeks (totalling 28 days) paid holidays each year, a minimum of 20-minute paid rest breaks for 6-hour work shifts, limits on night work or time spent on dangerous work, and a maximum 48-hour working week unless a worker individually consents. The Parental Leave Directive 2010 creates a bare minimum of 4 months of unpaid leave for parents (mothers, fathers, or legal guardians) to care for children before they turn 8 years old, and the Pregnant Workers Directive 1992 creates a right for mothers to a minimum of 14 weeks' paid leave to care for children.
Deployment of such agents began to accelerate in late 2023 after OpenAI's "function-calling" API was made available, and especially after Anthropic's late 2024 introduction of Model Context Protocol (MCP), a standardised way for LLM agents to gain contextual awareness, and to act on the world by calling various external tools. The term "agentic" only began to be used with any frequency in 2024, popularised in part by researcher Andrew Ng.
== Reversal == According to Goodwin, the dorsal slit operation may be reversed by suturing the cut ends together, which restores the tissue to its normal position and recreates the function of the foreskin.
A launch failure on 21 April 1964 in which the U.S. Transit-5BN-3 navigation satellite failed to achieve orbit and burned up on re-entry north of Madagascar. The 17,000 Ci (630 TBq) plutonium metal fuel in its SNAP-9a RTG was ejected into the atmosphere over the Southern Hemisphere where it burned up, and traces of plutonium-238 were detected in the area a few months later. This incident resulted in the NASA Safety Committee requiring intact reentry in future RTG launches, which in turn impacted the design of RTGs in the pipeline. The Nimbus B-1 weather satellite, whose launch vehicle was deliberately destroyed shortly after launch on 21 May 1968 because of erratic trajectory. Launched from the Vandenberg Air Force Base, its SNAP-19 RTG containing relatively inert plutonium dioxide was recovered intact from the seabed in the Santa Barbara Channel five months later and no environmental contamination was detected. In 1969 the launch of the first Lunokhod lunar rover mission failed, spreading polonium-210 over a large area of Russia. The failure of the Apollo 13 mission in April 1970 meant that the Lunar Module reentered the atmosphere carrying an RTG and burned up over Fiji. It carried a SNAP-27 RTG containing 44,500 Ci (1,650 TBq) of plutonium dioxide in a graphite cask on the lander leg which survived reentry into the Earth's atmosphere intact, as it was designed to do, the trajectory being arranged so that it would plunge into 6–9 kilometers of water in the Tonga trench in the Pacific Ocean.
Sources: en.wikipedia.org
Michel Chrétien (born March 26, 1936) is a Canadian medical researcher specializing in neuroendocrinology research at the Institut de recherches cliniques de Montréal, or Clinical Research Institute of Montreal, (IRCM). He is a younger brother of former Canadian prime minister, Jean Chrétien.
In late 1918, Poles hoping for a sovereign Poland started serious preparations for an uprising after Wilhelm II's abdication on 9 November 1918, which marked the end of the German Empire. The monarchy was replaced by the Weimar Republic. The uprising broke out on 27 December 1918 in Poznań, after a patriotic speech by Ignacy Paderewski, the famous pianist, who would become the Polish prime minister in 1919, with 2,000 men serving in the Guard and Security Service rising up in the city. The insurrectionist forces consisted of members of the Polish Military Organization, who formed the Straż Obywatelska (Citizen's Guard), later renamed as Straż Ludowa (People's Guard), which included many volunteers, who were mainly veterans of World War I. The first contingent to reach the Bazar Hotel, from where the uprising was initiated, was a 100-strong force from wildecka kompania Straży Ludowej (Wilda's People's Guard) led by Antoni Wysocki. The ruling body was the Naczelna Rada Ludowa (Supreme People's Council). Initially, the members of the council, including Captain Stanisław Taczak and General Józef Dowbor-Muśnicki were against the uprising, but they changed their minds in support of the insurrection on 9 January 1919. The timing was advantageous for the insurrectionists since between late 1918 and early 1919, internal conflict had weakened Germany, and many of its soldiers and sailors engaged in mutinous actions against the state. Demoralized by the signing of the armistice on 11 November 1918, the new German government was further embroiled in subduing the German Revolution.
National Capital Poison Center webPOISONCONTROL(R) Agency for Toxic Substances and Disease Registry American Association of Poison Control Centers American College of Medical Toxicology Clinical Toxicology Teaching Wiki Archived 2009-04-22 at the Wayback Machine Find Your Local Poison Control Centre Here (Worldwide) Poison Prevention and Education Website Cochrane Injuries Group Archived 2020-08-03 at the Wayback Machine, Systematic reviews on the prevention, treatment and rehabilitation of traumatic injury (including poisoning) Pick Your Poison—12 Toxic Tales by Cathy Newman
Moscow contains 1,696 high schools and 91 colleges. In addition, the city has 222 institutions of higher education, including 60 state universities and the Lomonosov Moscow State University (which was founded in 1755). The main university building in Vorobyovy Gory (Sparrow Hills) is 240 meters (790 ft) tall; when completed, it was the tallest building on the continent. The university enrols more than 30,000 undergraduate and 7,000 postgraduate students, who can choose among 29 faculties and 450 departments. The Moscow State University library contains more than nine million books, so it is one of the largest libraries in Russia. The I.M. Sechenov First Moscow State Medical University, named after Ivan Sechenov, formerly known as Moscow Medical Academy (1stMSMU), is a medical university in Moscow. It was founded in 1785 as the faculty of Moscow State University. It is a Russian Federal Agency for Health and Social Development. Moreover, it is one of the largest medical universities in Russia and Europe. More than 9200 students are enrolled in 115 academic departments; the university also offers courses for postgraduate studies.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.